ProCE Banner Activity

Venetoclax/Decitabine for Young Adults With Newly Diagnosed ELN Adverse-Risk AML: Phase II Trial Interim Analysis

Slideset Download
Conference Coverage
In young adults with newly diagnosed adverse-risk AML, venetoclax plus decitabine was associated with a composite CR rate of 76% and in a historical comparison showed a better efficacy and safety profile than cytarabine/idarubicin.

Released: December 13, 2021

Expiration: December 12, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation